Eikon Therapeutics
Clinical trials sponsored by Eikon Therapeutics, explained in plain language.
-
New combo therapy tackles tough tumors
Disease control CompletedThis early-phase trial tested a new drug called BDB001, alone or with another drug (pembrolizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. Only one person took part, so res…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New combo therapy tackles tough tumors
Disease control CompletedThis early-phase study tested an experimental drug called BDB001, given alone or with another cancer drug (pembrolizumab), in 87 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. This …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-phase study tested a new drug called BDB001, alone or with another drug (atezolizumab), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is complete, but resu…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Experimental drug BDB001 tested in just one patient with advanced cancer
Disease control CompletedThis early-phase trial tested a drug called BDB001 in people with advanced solid tumors that had stopped responding to standard immunotherapy (PD-1 or PD-L1 blockers). Only one person took part, and the main goal was to see if the tumor shrank. This is not a cure, and more resear…
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC